Abstract 3888: <i>TOP1</i> mutations mediate cross resistance to ADCs in metastatic breast cancer
Rachel O. Abelman(Massachusetts General Hospital), Aditya Bardia(UCLA Health), Beverly Moy(Global Cancer Institute), Laura M. Spring(Massachusetts General Hospital), Bogang Wu(George Washington University), Seth A. Wander(Harvard University), Ryan B. Corcoran(Massachusetts General Hospital), Arielle J. Medford(Harvard University), Andreas Varkaris(Massachusetts General Hospital), Haley Barnes(Massachusetts General Hospital), Leif W. Ellisen(Harvard University), Geoffrey Fell(Harvard University), Caroline Weipert(Guardant (United States)), Dejan Juric(Massachusetts General Hospital), Annika Putur(Massachusetts General Hospital)
Cited by 2
Related Papers
Circulating Tumor Cell Clusters Are Oligoclonal Precursors of Breast Cancer Metastasis
|Cell|2014|2.5k
Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition
|Science|2013|2.5k
Inertial Focusing for Tumor Antigen–Dependent and –Independent Sorting of Rare Circulating Tumor Cells
|Science Translational Medicine|2013|1.1k
Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
|New England Journal of Medicine|2019|1k